Trumps Signs Bill Allowing Terminal Patients to Try Unproven Medicines
WEDNESDAY, May 30, 2018 -- President Donald Trump on Wednesday put his signature on a bill allowing terminally ill patients to try unproven treatments to fight their disease.
Calling access to these drugs a "fundamental freedom," Trump said he hoped it would help save lives, the Associated Press reported.
The "Right to Try" bill passed the Senate in August, and the House passed the bill last week by a vote of 250-169, but not without fierce debate. Republicans contended it would help thousands of very ill Americans find new hope, while many Democrats said it might only provide false hope.
Trump had lauded the proposed measure in his State of the Union address. The new law allows people diagnosed with a life-threatening condition who've tried all other treatment options to receive unproven medicines without going to the U.S. Food and Drug Administration for permission.
The Goldwater Institute, a conservative public policy think tank based in Phoenix, helped craft the new policy and lobbied for the bill's passage. In a statement, institute president Victor Riches said that "federal law now protects the right of dying patients to obtain and use cutting-edge medicines without asking first for government permission."
Laura McLinn has a 9-year-old son, Jordan, with fatal Duchenne muscular dystrophy. In the Goldwater Institute news release, she said, "Jordan and I are grateful to see Right to Try signed into law today. During our more than three-year fight for patients to have this right, Jordan was accepted into a clinical trial for a drug we believe is slowing the progression of his fatal disease. We continued to fight for Right to Try for terminally ill patients who aren't in that 'lucky 3 percent' of the patient population who make it into trials."
But some experts worry that the new law will also make desperate, frail patients vulnerable to more harm, with FDA oversight taken away.
Without that guidance, "the rest of us doctors are kind of flying blind with respect to things like how much of the drug to give, how to give it, what kind of side effects to look for," Dr. Steven Joffe, professor in medical ethics and health policy at the University of Pennsylvania's Perelman School of Medicine, explained to CNN.
"So, by cutting the FDA out of the loop, you are failing to take advantage of the knowledge that it has about how to use the drug," he said. "About 10 percent of the time, the FDA, when it gets requests for expanded access, will say, 'Yes, but here's the way you can do it more safely' or 'Here's the side effects to look out for.'"
That guidance is now gone, Joffe said.
© 2020 HealthDay. All rights reserved.
Posted: May 2018
Read this next
THURSDAY, Oct. 22, 2020 -- If Obamacare, or the Affordable Care Act (ACA), is repealed, pediatric cancer patients could lose critical insurance coverage, a new study warns. Kids...
TUESDAY, Oct. 20, 2020 -- Actor Jeff Bridges announced on Monday that he has been diagnosed with lymphoma. Telling his fans on Twitter, the acclaimed thespian said, "Although it...
MONDAY, Oct. 12, 2020 -- Young women with cancer are at a high risk for employment and financial consequences, a new study finds. "Our study addresses the burden of employment...
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
- Monthly Update Archive
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.